Compare Krispy Kreme Inc (DNUT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Krispy Kreme Inc trades at $2.95 (market cap $521.37M), while Regeneron Pharmaceuticals Inc trades at $747.44 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 146× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays the higher dividend (3.47%). Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| DNUT | REGN | |
|---|---|---|
Market Cap | $521.37M | $76.14B |
Volume | 2,293,015 | 500,239 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $852.03 |
52-Week Low | $2.87 | $557.73 |
Typical Hold Time | 45 Days | 107 Days |
Enterprise Value | $1.76B | $70.85B |
Dividend Yield | 3.47% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $2.92, down 3.31% today, amid bearish technical signals and negative profitability. The company reported a significant net loss of $515.77M in 2025 despite $1.52B revenue, with negative margins and declining cash flow from operations. Recent news highlights ongoing legal investigations into fiduciary duties of officers and directors, creating investor uncertainty alongside seasonal product launches.
The outlook remains challenged by persistent losses and high debt levels, though analyst consensus leans bullish with 50% buy ratings. Key risks include legal overhangs, competitive pressure, and execution on profitability. Valuation metrics show mixed signals with low P/S but negative earnings, requiring careful monitoring of turnaround efforts and legal developments.
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
